Dimerix

Dimerix is a drug discovery company that can identify important drug targets called G Protein-Coupled Receptors. Dimerix’s lead DMX-200 candidate, a combination of irbesartan and propagermanium, is in a Phase 3 clinical trial.

30/05/2024 A second licensing deal

26/03/2024 Early success in Phase 3 clinical trial for FSGS

30/01/2024 A Phase 3 company priced like a Phase 2 company

12/04/2018 DMX-200’s credibility increases

08/11/2017 Dimerix is now a player in Diabetic Nephropathy

13/07/2017 Phase 2 success for DMX-200

27/03/2017 Progress with DMX-200

18/10/2016 Favourable interim data with DMX-200

25/08/2016 Hitting the GPCR spot

22 March 2024: We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB), about the company's encouraging interim results in the Phase 3 study of DMX-200 in Focal Segmental Glomerulosclerosis. This first interim analysis of the ACTION3 trial showed that the drug had performed well based on the proteinuria efficacy endpoint of the study. This suggests that DMX-200 may result in improvement in kidney function when included in the standard of care in patients with FSGS.

22 February 2024: We spoke with Dr Nina Webster, CEO of Dimerix (ASX: DXB), about the excellent economics behind DMX-200 for Focal Segmental Glomulerosclerosis (FSGS) and the near-term nature of the programme, with the first interim data from the current Phase 2 reading out shortly.

1 February 2024: We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB) about the important Phase 3 study of DMX-200 in a rare kidney disease called Focal Segmental Glomerulosclerosis. This study reads out its first interim analysis in mid-March 2024. A second analysis later in the trial can potentially open up accelerated approval of the drug.